Trial Profile
A Multi-center, Randomized, Double-blind, Active Controlled Study to Assess Efficacy, Safety and Tolerability of the Anti-IL13 Monoclonal Antibody QAX576 in the Treatment of Perianal Fistulas in Patients Suffering From Crohn's Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Dectrekumab (Primary) ; Infliximab
- Indications Crohn's disease; Rectal fistula
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Novartis
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01355614).
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov (NCT01355614).
- 24 Sep 2012 Planned end date changed from 1 Sep 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov (NCT01355614).